Conduit Pharmaceuticals Operating Income

Conduit Pharmaceuticals posts a operating income of $600M as of June 2026. That compares with $220M in the prior-year period — up 169.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Conduit Pharmaceuticals's operating income was $220M. The latest reading is $600M — a 169.5% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Conduit Pharmaceuticals's financial statement story. At $600M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CDT's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Conduit Pharmaceuticals's other metric pages and overview cover the third.